Cell culture-derived flu vaccine: Present and future

Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection

(2018) Andrés Pizzorno et al.   Scientific Reports

Respiratory Influenza A Virus Infection Triggers Local and Systemic Natural Killer Cell Activation via Toll-Like Receptor 7

(2018) Sabine Stegemann-Koniszewski et al.   Frontiers in Immunology

A systematic review of the health economic consequences of quadrivalent influenza vaccination

(2017) Pieter T. de Boer et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

(2017) Riju Ray et al.   Human Vaccines & Immunotherapeutics

Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to

(2016) Javier Diez-Domingo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study

(2016) Terry Nolan et al.   VACCINE

Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

(2015) Saverio Caini et al.   Influenza and Other Respiratory Viruses

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

(2015) Nagendra R Hegde   Human Vaccines & Immunotherapeutics

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines

(2015) Ernest Milián et al.   Biomed Research International

Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009–13

(2015) Ashley Fowlkes et al.   Lancet Respiratory Medicine

Prevalence of common food allergies in Europe: a systematic review and meta-analysis

(2014) B. I. Nwaru et al.   ALLERGY

Vaccines, new opportunities for a new society

(2014) R. Rappuoli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing

(2014) Ruben O. Donis et al.   VACCINE

Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

(2013) Andrea C Tricco et al.   BMC Medicine

Comparison of initial feasibility of host cell lines for viral vaccine production

(2013) Danielle H.W. Vlecken et al.   JOURNAL OF VIROLOGICAL METHODS

Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis

(2013) Harish Nair et al.   LANCET

Surveillance and Vaccine Effectiveness of an Influenza Epidemic Predominated by Vaccine-Mismatched Influenza B/Yamagata-Lineage Viruses in Taiwan, 2011−12 Season

(2013) Yi-Chun Lo et al.   PLoS One

Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor

(2013) Felipe Tapia et al.   VACCINE

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®)

(2013) Christof David Vinnemeier et al.   Human Vaccines & Immunotherapeutics

Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine

(2012) Candice Yuen-Yue Chan et al.   Expert Review of Vaccines

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production

(2012) Emanuele Montomoli et al.   Expert Review of Vaccines

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

(2012) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

(2012) Hiroyuki Fukase et al.   VACCINE

A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

(2012) Humberto Reynales et al.   VACCINE

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

(2012) Christoph Hatz et al.   VACCINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

(2012) David P. Greenberg et al.   VACCINE

Global production capacity of seasonal influenza vaccine in 2011

(2012) Jeffrey Partridge et al.   VACCINE

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

(2012) Agnieszka Szymczakiewicz-Multanowska et al.   Human Vaccines & Immunotherapeutics

In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells

(2012) Ramon Bencharitiwong et al.   Human Vaccines & Immunotherapeutics

The importance of influenza prevention for public health

(2012) Paloma Carrillo-Santisteve et al.   Human Vaccines & Immunotherapeutics

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010

(2011) et al.   Influenza and Other Respiratory Viruses

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

(2011) P Noel Barrett et al.   LANCET

Clinical development of a Vero cell culture-derived seasonal influenza vaccine

(2011) Hartmut J. Ehrlich et al.   VACCINE

In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy

(2010) Niya Wanich et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation

(2010) Yvonne Genzel et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

(2010) Sharon Frey et al.   CLINICAL INFECTIOUS DISEASES

Reverse genetic platform for inactivated and live-attenuated influenza vaccine

(2010) Eun-Ju Jung et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses

(2010) Aseem Pandey et al.   Human vaccines & immunotherapeutics

Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines

(2010) R. van Wielink et al.   JOURNAL OF VIROLOGICAL METHODS

The need for quadrivalent vaccine against seasonal influenza

(2010) Robert B. Belshe   VACCINE

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells

(2010) Althaf I. Hussain et al.   VACCINE

A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor

(2010) V. Lohr et al.   VACCINE

The Influenza Virus Enigma

(2009) Rachelle Salomon et al.   CELL

Influenza Vaccine Manufacture: Keeping Up with Change

(2009) Kathleen M. Neuzil et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

(2009) Agnieszka Szymczakiewicz‐Multanowska et al.   JOURNAL OF INFECTIOUS DISEASES

Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity

(2009) Keith S. Reisinger et al.   JOURNAL OF INFECTIOUS DISEASES

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of MDCK cells for production of live attenuated influenza vaccine

(2009) Jonathan Liu et al.   VACCINE

A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine

(2009) Rebecca J. Cox et al.   VACCINE

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

(2008) Jens-Peter Gregersen   VACCINE

Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin–Darby canine kidney cells

(2008) Keiichi Makizumi et al.   VACCINE

Canine MDCK cell lines are refractory to infection with human and mouse prions

(2008) Magdalini Polymenidou et al.   VACCINE

Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells

(2007) Kiyoto Nishiyama et al.   BIOLOGICALS